By: Becky Ditty, MS
The Medical Device User Fee Act (MDUFMA) I, signed into law on October 26, 2002, authorized FDA to collect user fees for various marketing applications, including premarket notifications (510(k)s). The fees...
By: Christy Foreman, MBE and Becky Ditty, MS
You are working on creating a novel new device. It is an exciting time! But with novelty comes many unanswered questions, including what is the best regulatory pathway. The Breakthrough Device Program may be a part of that pathway.
By: Samie Allen, MBA and Joshua Crist, MSE
It can be hard to keep up with the rapid pace of changes in FDA’s regulations and review policies for medical devices. One area that changes roughly every 5 years in some capacity is the organizational structure of..
By: Miriam Provost, PhD and Samie Allen, MBA
In recent years, the FDA has overhauled the De Novo program to make it simpler and more attractive to medical device manufacturers. One of the areas of focus has been the program for De Novo classifications...
By: Ronald A. Salerno, PhD, Kerin Ablashi, MS, Debra Barngrover, PhD, RAC and Kelly Reich MS, RAC
In this paper, the authors call upon their years of experience preparing meeting requests and meeting packages, participating in pre-IND meetings, and reviewing and responding to pre-IND meeting comments from the FDA in order to provide recommendations to organizations looking to make the most out of their pre-IND meeting with FDA.
By: Paul W. Price, PhD, Senior Consultant
The global concern about Zika virus continues to grow as the international community braces for its continued spread.
By: John R. Godshalk, MSE, MBA, Senior Consultant
Data integrity has always played an essential role in regulatory application review and cGMP inspections – a trend that will only continue to grow in the coming years.